When to Avoid Keeps: Specific Patient Profiles That Should Look Elsewhere for Hair Loss Treatment

What Keeps Actually Offers, and Why That Scope Matters

Keeps markets itself as a one-stop subscription service for male hair loss, delivering finasteride and minoxidil directly to members after an asynchronous or synchronous online consultation. The platform is legitimate in a narrow technical sense: prescribers are licensed US physicians, prescriptions are issued through licensed pharmacies, and the company holds LegitScript certification, which requires compliance with applicable pharmacy and telehealth laws.

Legitimacy is not the same as universal suitability. The drugs Keeps prescribes carry real pharmacological risks that a short online intake form may not fully surface. Understanding those risks, and who carries them, is the only way to make an informed decision about whether a D2C hair loss subscription is the right channel for your care.

What the Intake Form Can and Cannot Detect

Keeps uses a self-reported questionnaire and, in most states, a photo-based review by a remote physician. This workflow cannot replace a physical exam, a prostate-specific antigen (PSA) blood draw, or a structured psychiatric screening tool such as the PHQ-9. Men whose contraindications require laboratory data or hands-on assessment are poorly served by asynchronous telehealth, regardless of the brand involved.

The FDA label for finasteride 1 mg (Propecia) states that a baseline PSA should be established before treatment and that PSA values are reduced approximately 50% by the drug, requiring adjustment when screening for prostate cancer. [1] A platform that does not order baseline labs before prescribing cannot fulfill that clinical requirement.

How Keeps Compares to a Dermatology or Urology Visit

An in-person dermatologist or urologist can perform a scalp biopsy to rule out non-androgenetic causes of hair loss (alopecia areata, scarring alopecias, tinea capitis), order a complete blood count and thyroid panel, and conduct a structured digital rectal exam if indicated. Keeps does none of these. For straightforward male androgenetic alopecia (AGA) in a healthy young man with no complicating factors, that gap may not matter. For anyone outside that narrow profile, it is a meaningful clinical gap.

Men Who Should Not Use Keeps Without Specialist Clearance First

Several well-defined patient profiles carry contraindications or elevated risk that make Keeps an inappropriate first stop. Each is addressed individually below.

Men With Any Prostate Cancer History or Elevated PSA

Finasteride is a 5-alpha reductase inhibitor (5-ARI). The PCPT trial (N=18,882) found that 5-ARI use was associated with a 24.8% relative reduction in prostate cancer prevalence but a statistically significant increase in high-grade (Gleason 7 to 10) tumors in the treatment arm. [2] The FDA updated the finasteride label in 2011 to reflect this finding, adding language about the potential increased risk of high-grade prostate cancer. [1]

Any man with a personal history of prostate cancer, a PSA above the age-adjusted normal range, or a first-degree relative with prostate cancer diagnosed before age 65 should see a urologist before starting a 5-ARI through any channel, including Keeps.

Men With a History of Sexual Dysfunction or Concern About Post-Finasteride Syndrome

Finasteride reduces serum dihydrotestosterone (DHT) by approximately 70% at the 1 mg dose. [3] Controlled trials of finasteride 1 mg reported rates of sexual adverse effects, including decreased libido, erectile dysfunction, and ejaculatory disorders, ranging from 3.4% to 15.8% depending on the study and definition used. [4]

A subset of men report persistent sexual, neurological, and psychological symptoms that continue after stopping the drug. This cluster is described in the literature as Post-Finasteride Syndrome (PFS). The FDA added a label update in 2012 noting that libido disorders, ejaculation disorders, and orgasm disorders may persist after discontinuation in some patients. [1] The PFS Foundation maintains a patient registry, and a 2017 case series published in the Journal of Clinical Psychiatry documented suicidal ideation in PFS patients. [5]

Men who already report low libido, erectile dysfunction, or depressive symptoms are at elevated baseline risk for adverse psychological and sexual effects. A D2C questionnaire is insufficient to assess this risk adequately.

Men With Depression, Anxiety, or Active Psychiatric Treatment

The neurosteroid pathway is directly affected by 5-alpha reductase inhibition. Finasteride reduces allopregnanolone, a neuroactive steroid with GABAergic properties. [6] Several observational studies and case reports have linked finasteride use to new-onset or worsening depression. A 2020 cohort study published in JAMA Dermatology (N=11,505 exposed men) found that men taking oral finasteride had a statistically higher hazard of depression (adjusted hazard ratio 1.79, 95% CI 1.05 to 3.04) compared to unexposed men. [7]

Men currently managed for depression, anxiety, or any other psychiatric condition should discuss finasteride with their prescribing psychiatrist before starting. A Keeps intake form is not equipped to perform that safety check.

Men With Cardiovascular Disease or Hypotension

Topical minoxidil at 2% and 5% concentrations produces minimal systemic absorption in most users, but absorption increases with scalp irritation, dermatitis, or application to large surface areas. [8] Oral minoxidil at hair-loss doses (0.625 to 5 mg daily) carries enough systemic absorption to produce measurable blood pressure and heart rate effects in some patients.

The FDA black-box warning on oral minoxidil (at antihypertensive doses) specifies that the drug can cause serious adverse cardiovascular effects including pericardial effusion, pericarditis, and cardiac tamponade, and that it must be used with a beta-blocker and a diuretic. [9] While hair-loss doses are substantially lower than antihypertensive doses (typically 10 to 40 mg daily), men with pre-existing hypotension, heart failure, or significant cardiovascular disease should not start any form of minoxidil through a D2C platform without cardiology input.

Men Trying to Conceive

Finasteride is not approved for women, but the male fertility angle is less frequently discussed. Finasteride reduces DHT in seminal plasma. Small studies have reported decreased semen volume and sperm count in men taking finasteride, though findings are not consistent across all trials. [10] Men actively trying to conceive with a partner should disclose finasteride use to a reproductive urologist and consider a baseline semen analysis before starting treatment.

Men Outside the Androgenetic Alopecia Diagnosis

Keeps treats one condition: androgenetic alopecia (male pattern baldness, Hamilton-Norwood classification I, VII). If a man's hair loss follows an unusual pattern, is associated with systemic symptoms (fatigue, weight change, skin changes), is diffuse rather than patterned, or has been rapid in onset, a different diagnosis may be the cause.

Conditions that mimic AGA include alopecia areata (an autoimmune condition treated with JAK inhibitors or intralesional corticosteroids, not finasteride), telogen effluvium (often self-limiting, triggered by illness or nutritional deficiency), tinea capitis (a fungal infection requiring antifungal treatment), and scarring alopecias such as lichen planopilaris. [11] A D2C photo-based consultation cannot reliably distinguish these from AGA. Misdiagnosis leads to ineffective treatment and delayed appropriate care.

Evaluating Keeps' Legitimacy: What the Evidence Actually Shows

A framework for evaluating any D2C telehealth brand's legitimacy should cover four dimensions: regulatory compliance, prescriber credentials, pharmacy standards, and post-market safety monitoring.

Regulatory and Certification Status

Keeps holds LegitScript certification, a third-party verification program that confirms compliance with applicable laws, requires licensed prescribers, and mandates that pharmacies used be licensed in the states served. LegitScript's standards are publicly documented and audited periodically.

The FDA does not certify telehealth platforms directly, but the drugs Keeps prescribes (finasteride 1 mg and topical minoxidil) are FDA-approved for male AGA when prescribed within label indications. Oral minoxidil at hair-loss doses is off-label, which is lawful but means the prescriber carries greater responsibility for informed consent.

Prescriber and Pharmacy Standards

Keeps states that all prescribers are US-licensed physicians. State medical boards publish licensure verification tools. Before subscribing to any telehealth service, patients can verify their assigned prescriber's license at their state medical board website. This takes approximately two minutes and is always worth doing.

Prescriptions are filled through licensed compounding or retail pharmacies depending on the product. Patients have the right to request the pharmacy name and verify its license through the National Association of Boards of Pharmacy (NABP) at nabp.pharmacy.

Common Complaints and What They Signal

A review of public complaint boards (BBB, Trustpilot, Reddit's r/tressless) reveals a recurring pattern of Keeps complaints: difficulty canceling subscriptions, unexpected charges after cancellation, and slow or non-responsive customer service. These are operational issues with the business model, not safety failures, but they are worth factoring into a decision.

One category of complaint that does carry clinical significance is reports of prescriptions being continued without any follow-up contact from a physician. Finasteride prescriptions should, per standard of care, include periodic reassessment of PSA and symptom review. Men who receive refills indefinitely without any check-in should ask their Keeps physician explicitly for a documented medication review.

Finasteride 1 mg: The Risk-Benefit Math in Plain Numbers

Finasteride 1 mg was studied in two key trials that supported FDA approval. The 5-year efficacy trial (N=1,553) showed that 48% of men taking finasteride maintained or increased hair count versus 14% in the placebo group, and 42% showed visible improvement versus 7% placebo at year two, as reported in the finasteride prescribing information and supporting literature. [4]

Sexual adverse effects occurred in 3.8% of finasteride-treated men versus 2.1% of placebo-treated men in the 1-year key trial, a difference of 1.7 percentage points. [4] This absolute risk difference is modest at the population level but clinically significant at the individual level for men with baseline vulnerabilities.

The Endocrine Society's clinical practice guideline on androgen therapy notes that DHT is essential for maintaining prostate, sexual, and neurological function in adult men, and that pharmacological suppression of DHT requires careful patient selection and monitoring. [12] That guidance applies to finasteride regardless of the prescribing channel.

Oral Minoxidil for Hair Loss: The Off-Label Calculus

Oral minoxidil at 0.625 to 5 mg daily has gained substantial off-label use for AGA and female pattern hair loss. A 2022 systematic review in the Journal of the American Academy of Dermatology (JAAD) covering 16 studies found that low-dose oral minoxidil produced hair density improvement in the majority of participants, with hypertrichosis (unwanted body hair growth) reported in 14.9 to 80% of subjects and fluid retention in a smaller subset. [13]

The FDA's approved oral minoxidil labeling (at antihypertensive doses) includes a black-box warning for pericardial effusion and exacerbation of angina. [9] At hair-loss doses, these events are rare but not zero. Men with uncontrolled hypertension, hypotension, or any form of structural heart disease should avoid oral minoxidil outside a cardiology-supervised setting.

A blood pressure measurement at baseline is a minimum requirement before starting oral minoxidil. Keeps' asynchronous intake may not consistently capture an actual measured BP value, relying instead on self-report.

What to Do If You Are in One of These Risk Groups

Men in any of the flagged categories have several better-suited pathways:

A board-certified dermatologist with a subspecialty in hair disorders (trichology-trained) can perform a dermoscopy exam, order relevant labs (ferritin, thyroid-stimulating hormone, complete blood count, PSA), and prescribe the same medications with more complete baseline data. The American Academy of Dermatology's Find a Dermatologist tool at aad.org allows filtering by specialty.

Men concerned specifically about the psychiatric or sexual effects of finasteride should start with their primary care physician or psychiatrist, who can perform a structured baseline assessment (PHQ-9 for depression, validated sexual function scale such as the IIEF-5) before initiating treatment.

Men with any prostate concern should see a urologist who can perform a digital rectal exam, draw a baseline PSA, and contextualize family history before any 5-ARI prescription is written.

None of this means Keeps is categorically unsafe. For a 28-year-old man with classic Hamilton-Norwood III vertex pattern, no psychiatric history, no cardiovascular disease, no prostate concerns, and a straightforward desire for finasteride and minoxidil, the Keeps workflow is a reasonable and cost-effective access point. The platform becomes inappropriate when the clinical picture deviates from that simple baseline.

A baseline PSA drawn before starting finasteride, as stated in the drug's FDA label, remains the single most actionable safety step that the Keeps model currently does not reliably provide. [1]